oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 A Review of the in Adults with Overweight or (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity Weight Regain after Stopping Obesity

Allergic Reactions (Rare): Although rare, some individuals can have an allergic reaction to the injection, ranging from a rash or itching to more severe symptoms like swelling of the face, tongue, or throat, dizziness, or difficulty breathing

The medication remains in Phase 3 clinical trials

During sleep, free radicals are removed as the body repairs and rejuvenates

Future research should prioritize well-designed, longitudinal clinical trials to assess its long-term safety and efficacy, alongside pharmacokinetic studies to better understand its metabolic pathways and therapeutic impact

For type 2 diabetes, NICE-recommended alternatives include metformin (first-line), SGLT2 inhibitors, DPP-4 inhibitors, and insulin therapy, each with distinct mechanisms and side-effect profiles

23:e13383